Neal C. Bradsher - 01 Jul 2025 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director, 10%+ Owner
Signature
/s/ Neal C. Bradsher
Issuer symbol
LCTX
Transactions as of
01 Jul 2025
Net transactions value
$0
Form type
4
Filing time
03 Jul 2025, 14:45:11 UTC
Previous filing
03 Jul 2024
Next filing
10 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bradsher Neal C Director, 10%+ Owner C/O BROADWOOD CAPITAL, INC., 156 WEST 56TH STREET, 3RD FLOOR, NEW YORK /s/ Neal C. Bradsher 03 Jul 2025 0001278388

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX OPTION TO PURCHASE COMMON SHARES Award $0 +75,000 $0.000000 75,000 01 Jul 2025 COMMON SHARES 75,000 $0.8977 Direct F1, F2
holding LCTX OPTION TO PURCHASE COMMON SHARES 75,000 01 Jul 2025 COMMON SHARES 75,000 $0.9541 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 50,000 01 Jul 2025 COMMON SHARES 50,000 $1.41 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 50,000 01 Jul 2025 COMMON SHARES 50,000 $1.57 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 50,000 01 Jul 2025 COMMON SHARES 50,000 $2.86 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 40,000 01 Jul 2025 COMMON SHARES 40,000 $0.8263 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 40,000 01 Jul 2025 COMMON SHARES 40,000 $1.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options will vest and become exercisable on the earlier of: (a) July 1, 2026 and (b) the date of Lineage Cell Therapeutics, Inc.'s (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.
F2 These options were granted to the Reporting Person by the Issuer on July 1, 2025 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
F3 These options are currently exercisable.